Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway

Lamprini Veneti, Beatriz Valcarcel Salamanca, Elina Seppälä, Jostein Starrfelt, Margrethe Larsdatter Storm, Karoline Bragstad, Olav Hungnes, Håkon Bøås, Reidar Kvåle, Line Vold, Karin Nygård, Eirik Alnes Buanes, Robert Whittaker
doi: https://doi.org/10.1101/2021.09.02.21263014
Lamprini Veneti
aDepartment of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(MSc)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatriz Valcarcel Salamanca
bDepartment of Method Development and Analytics, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elina Seppälä
cDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(MD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jostein Starrfelt
aDepartment of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margrethe Larsdatter Storm
dDepartment of Infectious Disease Registries, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karoline Bragstad
eDepartment of Virology, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olav Hungnes
eDepartment of Virology, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Håkon Bøås
aDepartment of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reidar Kvåle
fDepartment of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway
gDepartment of Clinical Medicine, University of Bergen, Bergen, Norway
(MD, PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Line Vold
aDepartment of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(DVM, PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Nygård
aDepartment of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(DVM, PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eirik Alnes Buanes
fDepartment of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway
hNorwegian Intensive Care and Pandemic Registry, Haukeland University Hospital, Bergen, Norway
(MD, PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Whittaker
cDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway
(MSc)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Robert.Whittaker@fhi.no
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To estimate the risk of hospitalisation among reported cases of the Delta-variant of SARS-CoV-2 compared to the Alpha variant in Norway. We also estimated the risk of hospitalisation by vaccination status.

Methods We conducted a cohort study on laboratory-confirmed cases of SARS-CoV-2 in Norway, diagnosed between 3 May and 15 August 2021. We calculated adjusted risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable binomial regression, accounting for variant, vaccination status, demographic characteristics, week of sampling and underlying comorbidities.

Results We included 7,977 cases of Delta and 12,078 cases of Alpha. Overall, 347 (1.7%) cases were hospitalised. The aRR of hospitalisation for Delta compared to Alpha was 0.97 (95%CI 0.76–1.23). Partially vaccinated cases had a 72% reduced risk of hospitalisation (95%CI 59%–82%), and fully vaccinated cases had a 76% reduced risk (95%CI 61%–85%), compared to unvaccinated cases.

Conclusions We found no difference in the risk of hospitalisation for Delta cases compared to Alpha cases in Norway. Further research from a wide variety of settings is needed to better understand the association between the Delta variant and severe disease. Our results support the notion that partially and fully vaccinated persons are highly protected against hospitalisation with COVID-19.

Highlights

  • The SARS-CoV-2 Delta variant has dominated in Norway since July 2021

  • There was no difference in the risk of hospitalisation for Delta cases compared to Alpha

  • Partially and fully vaccinated cases had >70% decreased risk of hospitalisation

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for this study was granted by Regional Committees for Medical Research Ethics - South East Norway, reference number 249509. The need for informed consent was waived by the ethics committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets analysed during the current study come from the national emergency preparedness registry for COVID-19, housed at the Norwegian Institute of Public Health. The preparedness registry comprises data from a variety of central health registries, national clinical registries and other national administrative registries. Further information on the preparedness registry, including access to data from each data source, is available at https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
Lamprini Veneti, Beatriz Valcarcel Salamanca, Elina Seppälä, Jostein Starrfelt, Margrethe Larsdatter Storm, Karoline Bragstad, Olav Hungnes, Håkon Bøås, Reidar Kvåle, Line Vold, Karin Nygård, Eirik Alnes Buanes, Robert Whittaker
medRxiv 2021.09.02.21263014; doi: https://doi.org/10.1101/2021.09.02.21263014
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
Lamprini Veneti, Beatriz Valcarcel Salamanca, Elina Seppälä, Jostein Starrfelt, Margrethe Larsdatter Storm, Karoline Bragstad, Olav Hungnes, Håkon Bøås, Reidar Kvåle, Line Vold, Karin Nygård, Eirik Alnes Buanes, Robert Whittaker
medRxiv 2021.09.02.21263014; doi: https://doi.org/10.1101/2021.09.02.21263014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)